Researchers at the University of Alabama at Birmingham first isolated the kinase HIPK2 from among hundreds of potential targets by using bioinformatics to hone in on the protein kinase as a target for study.
Restoring a signaling kinase in the heart muscle could hold the key to treating heart failure, which has emerged as a rising cause of death among older adults.
Researchers at the University of Alabama at Birmingham first isolated the kinase HIPK2 from among hundreds of potential targets by using bioinformatics to hone in on the protein kinase as a target for study. “Among those candidates, we identified a potential modulator of heart failure—HIPK2, a kinase whose role in cardiac biology has never been studied before,” Hind Lal, PhD, senior author of the study, said in a statement.
The findings were recently published in the journal Circulation, the official journal of the American Heart Association.
“To determine the role of HIPK2 in human hearts, we examined the expression of HIPK2 in heart tissue from patients with end-stage ischemic cardiomyopathy,” Lal said. “The expression of HIPK2 was dramatically decreased in failing hearts compared with normal human hearts.”
After identifying HIPK2 as the target for study, Lal’s team set up several tests. First, they deleted the HIPK2 protein from heart muscle cells to see if this caused heart muscle deterioration. They observed enhanced programmed cell death, or apoptosis, at the molecular level, in the cells of the heart muscle.
Then, they tested the idea of adding the kinase back once it was depleted. The team wanted to see if restoring kinase back to in the “knockout mice” would save them from heart failure, because this would suggest a future treatment. They used gene therapy to add overexpression of the kinase MEK1 to the knockout heart muscle cells; this protein restored impaired signaling of ERK phosphorylation in the knockout mice and slowed the cell death.
Finding treatments to slow or reverse heart failure is a priority as the population ages, because heart failure is becoming a more common cause of death. A recent study appearing in JAMA Cardiology found that the rate of death and the total number of deaths with heart failure as the underlying cause have increased substantially between 2011 and 2017. The researchers from Kaiser Permanente reported a 20.7% increase in the age-adjusted mortality rate for heart failure and a 38% increase in the number of heart failure deaths.
The so-called “silver tsunami” has many implications, and pharmaceutical leaders are pointing to the drug class of sodium glucose co-transporter 2 (SGLT2) inhibitors, first approved to treat type 2 diabetes, as a potential solution. The drug class has been shown to reduce hospitalization for heart failure. Last month, FDA approved the SGLT2 inhibitor dapagliflozin to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.
Reference
Guo Y, Sui JY, Kim K, et al. Cardiomyocyte HIPK2 maintains basal cardiac function via ERK signaling [published online October 4, 2019]. Circulation. doi: 10.1161/CIRCULATIONAHA.119.04074.
Severe Prenatal Grief May Increase Child’s Heart Failure Risk
March 12th 2024Research found that maternal loss of a partner or older child, as well as the loss of a close relative due to unnatural causes in the year before or during pregnancy, were linked to a heightened risk of heart failure in offspring.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
There Is No Interaction Between BMI and SGLT2 Inhibitor Efficacy in HF, Review Finds
February 23rd 2024Among patients with heart failure (HF), those taking dapaglifozin or empaglifozin had a 30% odds reduction in HF hospitalization, 14% odds reduction in cardiovascular mortality, and a 10% odds reduction in all-cause mortality compared with patients taking placebo.
Read More
Intermountain Healthcare and Story Health Partner to Optimize Rural Heart Failure Care
February 7th 2023On this episode of Managed Care Cast, we speak with Tom Stanis, CEO and cofounder of Story Health, and Phillip Wood, Intermountain Ventures program director, on how their partnership came about, how it is going so far, and the future of their collaboration.
Listen
Permanent Pacemaker Implantation Frequently Follows Tricuspid Valve Surgery, Study Finds
February 5th 2024Among Medicare beneficiaries, implantation was especially frequent for female patients and those undergoing tricuspid valve replacement with or without concomitant left-sided heart surgeries.
Read More
Low Muscle Mass, Hypoalbuminemia Increase Mortality Risk in ADHF
January 28th 2024Patients admitted to the hospital with acute decompensated heart failure (ADHF) who also had low muscle mass and hypoalbuminemia experienced a heightened mortality risk, suggesting skeletal muscle mass and serum albumin are important prognostic factors.
Read More